ICU Medical (NASDAQ:ICUI) Issues FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 7.750-8.450 for the period, compared to the consensus EPS estimate of 7.740. The company issued revenue guidance of -.

ICU Medical Price Performance

Shares of ICU Medical stock traded up $3.32 during mid-day trading on Friday, reaching $126.39. 274,213 shares of the stock were exchanged, compared to its average volume of 275,408. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The firm has a 50-day simple moving average of $128.93 and a 200 day simple moving average of $138.35. The company has a current ratio of 2.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.60. The company has a market cap of $3.16 billion, a price-to-earnings ratio of 6,310.56, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The business had revenue of $535.94 million for the quarter, compared to the consensus estimate of $541.20 million. During the same period last year, the company posted $2.11 EPS. ICU Medical’s revenue for the quarter was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts predict that ICU Medical will post 6.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ICUI shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Piper Sandler decreased their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a research note on Thursday. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, KeyCorp decreased their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research note on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $169.00.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q1 results beat expectations — ICU reported EPS of $1.97 vs. consensus ~$1.78 and revenue of ~$525.8M that beat estimates. Stronger-than-expected EPS drove immediate bullish sentiment. ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: FY‑2026 EPS guidance raised/confirmed to a range of 7.750–8.450, slightly above the sell‑side consensus — guidance that roughly meets or edges past expectations supports the upbeat analyst reactions. ICU Medical Announces First Quarter 2026 Results
• Positive Sentiment: Analyst actions add momentum — Jefferies upgraded ICUI to “strong-buy” and Piper Sandler reaffirmed a buy rating, which can drive buying interest from institutional and momentum traders. Jefferies Upgrade / Coverage Note Piper Sandler Reaffirms Buy
• Neutral Sentiment: Options activity shows elevated implied volatility — surging IV indicates traders expect bigger near‑term moves (could amplify upside or downside volatility). Watch option skew and volume for directional conviction. Implied Volatility Surging for ICU Medical Stock Options
• Neutral Sentiment: Management commentary and slides available — the earnings call transcript and presentation provide detail on drivers (costs, mix, timing) and should inform whether beats are sustainable. Investors should review the call for margin and order‑book color. Q1 2026 Earnings Call Transcript Q1 Results Presentation
• Negative Sentiment: Top-line weakness and thin margins remain a concern — revenue was down double digits year‑over‑year (~12–14% depending on the report) and reported net margin is near zero, which raises questions about sustainability of earnings if volumes don’t recover. This pressure could limit upside without clear signs of recovery. ICU Medical: Q1 Earnings Snapshot

Institutional Investors Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently modified their holdings of ICUI. Smartleaf Asset Management LLC lifted its holdings in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of ICU Medical during the second quarter worth $177,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of ICU Medical during the fourth quarter worth $203,000. Panagora Asset Management Inc. acquired a new stake in shares of ICU Medical during the fourth quarter worth $205,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of ICU Medical during the fourth quarter worth $216,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.